Quantcast

Latest Mast Therapeutics Inc. Stories

2014-06-19 16:26:20

SAN DIEGO, June 19, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development. "We are delighted to welcome Howard to the Board," stated Jack Lief, Chair of Mast's Board of Directors. "His medical training and extensive clinical development and...

2014-06-16 08:28:24

Sub-study will investigate effects of MST-188 on tissue oxygenation in sickle cell disease patients experiencing a vaso-occlusive crisis SAN DIEGO, June 16, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be...

2014-05-09 16:22:56

Editor Note: For more information about this release, please scroll to bottom. LONDON, May 9, 2014 /PRNewswire/ -- On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the...

2014-05-05 08:28:17

SAN DIEGO, May 5, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2014. During the period, the Company made progress across multiple clinical and corporate fronts, including the ex?U.S. expansion of EPIC, it's pivotal Phase 3 study of MST-188 in sickle cell disease, and pipeline expansion with the acquisition of AIR001, a clinical-stage program. Other highlights included initiating a Phase 2 study of...

2014-04-14 12:33:36

MST-188 decreased a marker of inflammation and red blood cell aggregation (50% reduction relative to control) SAN DIEGO, April 14, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in an ex vivo study conducted at Loyola University Medical Center, MST-188 reduced the mean erythrocyte sedimentation rate (ESR) by 50% relative to control in blood collected from individuals with sickle cell disease. ESR, a common laboratory test and measure of inflammation,...

2014-03-26 08:29:24

SAN DIEGO, March 26, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2013. "2013 was a year of great progress for Mast as we delivered on our operational goal of opening 40 clinical sites in the U.S. for EPIC, our pivotal Phase 3 study of MST-188 in sickle cell disease," said Brian M. Culley, Chief Executive Officer. "Already in 2014, we've achieved numerous operational and strategic...

2014-03-26 08:28:59

- Study will evaluate whether MST-188 improves the effectiveness of rt-PA SAN DIEGO, March 26, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that it has initiated a phase 2, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in patients with acute lower limb ischemia. Acute limb ischemia (ALI), an acute complication of peripheral arterial disease, describes a sudden decrease in perfusion...

2014-03-11 08:29:47

SAN DIEGO, March 11, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that the United States Adopted Names (USAN) Council has selected "vepoloxamer" as the unique non-proprietary (generic) name for the active pharmaceutical ingredient (API) in MST-188, the Company's lead product candidate. Mast sought a unique name for its API to clearly identify it as different from non-purified poloxamers. In support of its application, the Company argued that drug...

2014-02-27 16:27:40

SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension. "The addition of AIR001 provides us with not only an exciting phase 2 asset in the area of pulmonary disease,...

2014-02-25 08:31:56

SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Cowen & Co. 34(th) Annual Healthcare Conference on Monday, March 3, 2014 at 4:50 p.m. Eastern time at The Boston Marriott Copley Place Hotel in Boston. Interested parties can access a live audio webcast and slide presentation on the Mast Therapeutics web site at www.masttherapeutics.com. An archived...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related